Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

Journal of Thoracic Oncology

Volumn 14, Issue 3, 2019, Pages 343-357

  Seijo, Luis M ^a,b   Peled, Nir ^c   Ajona, Daniel ^d,e,f,g   Boeri, Mattia ^h   Field, John K ⁱ   Sozzi, Gabriella ^h   Pio, Ruben ^d,e,f,g   Zulueta, Javier J ^a,j   Spira, Avrum ^k   Massion, Pierre P ^l   Mazzone, Peter J ^m   Montuenga, Luis M ^d,e,f,n  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d UNIVERSITY OF NAVARRA   (Spain)

^e IdiSNA Navarra Institute for Health Research   (Spain)

^f Autonomous University of Madrid Instituto de Investigación Hospital Universitario La Paz   (Spain)

^g UNIVERSITY OF NAVARRA   (Spain)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^j VisionGate Inc   (United States)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l VANDERBILT INGRAM CANCER CENTER   (United States)

^m LERNER RESEARCH INSTITUTE   (United States)

ⁿ UNIVERSITY OF NAVARRA   (Spain)

more..

Author keywords

Biomarkers; Clinical utility; Lung cancer; Screening; Test validation; Trial design

Indexed keywords

BIOLOGICAL MARKER; CHLOROPLAST DNA; CIRCULATING TUMOR DNA; COMPLEMENT COMPONENT C4D; MICRORNA; TUMOR MARKER;

ARTIFICIAL INTELLIGENCE; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DNA METHYLATION; GENETIC PREDISPOSITION; HUMAN; IMAGE ANALYSIS; LUNG CANCER; LUNG CARCINOGENESIS; MASS FRAGMENTOGRAPHY; METABOLOMICS; NEXT GENERATION SEQUENCING; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; EARLY CANCER DIAGNOSIS; GENETICS; LUNG TUMOR; METABOLISM; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; PROGNOSIS;

EID: 85060116337     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2018.11.023     Document Type: Review

References (131)

1. Aberle, D.R., Adams, A.M., Berg, C.D., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (2011), 395–409.
2. Henschke, C.I., Shaham, D., Yankelevitz, D.F., et al. CT screening for lung cancer: significance of diagnoses in its baseline cycle. Clin Imaging 30 (2006), 11–15.
3. Yousaf-Khan, U., Van Der Aalst, C., De Jong, P.A., et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax 72 (2017), 48–56.
4. De Koning H, Van Der Aalst C, ten Haaf K, Oudkerk M. Effects of volume CT lung cancer screening: mortality results of the NELSON randomized-controlled population trial. Paper presented at: 19th World Conference on Lung Cancer. September 23–26, 2018; Toronto, Canada.
5. Oudkerk, M., Devaraj, A., Vliegenthart, R., et al. European position statement on lung cancer screening. Lancet Oncol 18 (2017), e754–e766.
6. Moyer, V.A., Screening for lung cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 160 (2014), 330–338.
7. Roberts, H., Walker-Dilks, C., Sivjee, K., et al. Screening high-risk populations for lung cancer: guideline recommendations. J Thorac Oncol 8 (2013), 1232–1237.
8. Mazzone, P.J., Silvestri, G.A., Patel, S., et al. Screening for lung cancer: CHEST guideline and expert panel report. Chest 153 (2018), 954–985.
9. Sanchez-Salcedo, P., Wilson, D.O., De-Torres, J.P., et al. Improving selection criteria for lung cancer screening: the potential role of emphysema. Am J Respir Crit Care Med 191 (2015), 924–931.
10. Pinsky, P.F., Berg, C.D., Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?. J Med Screen 19 (2012), 154–156.
11. Tammemägi, M.C., Katki, H.A., Hocking, W.G., et al. Selection criteria for lung-cancer screening. N Engl J Med 368 (2013), 728–736.
12. Tanner, N.T., Dai, L., Bade, B.C., Gebregziabher, M., Silvestri, G.A., Assessing the generalizability of the National Lung Screening Trial: comparison of patients with stage 1 disease. Am J Respir Crit Care Med 196 (2017), 602–608.
13. Wood, D.E., POINT: should lung cancer screening be expanded to persons who don't currently meet accepted criteria set forth by the CHEST guidelines on lung cancer screening? Yes. Chest 153 (2018), 1299–1302.
14. Tammemagi, C.M., Pinsky, P.F., Caporaso, N.E., et al. Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst 103 (2011), 1058–1068.
15. ten Haaf, K., Jeon, J., Tammemägi, M.C., et al. Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. PLoS Med, 14, 2017, e10002277.
16. Wang, J., Liu, Q., Yuan, S., et al. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. Sci Rep, 7, 2017, 8371.
17. De-Torres, J.P., Wilson, D.O., Sanchez-Salcedo, P., et al. Lung cancer in patients with chronic obstructive pulmonary disease: development and validation of the COPD lung cancer screening score. Am J Respir Crit Care Med 191 (2015), 285–291.
18. Van Riel, S.J., Ciompi, F., Winkler Wille, M.M., et al. Malignancy risk estimation of pulmonary nodules in screening CTs: comparison between a computer model and human observers. PLoS One, 12, 2017, e0185032.
19. Tammemagi, M.C., Schmidt, H., Martel, S., et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. Lancet Oncol 18 (2017), 1523–1531.
20. Peled, N., Ilouze, M., Screening for lung cancer: what comes next?. J Clin Oncol 33 (2015), 3847–3848.
21. Amos, C.I., Dennis, J., Wang, Z., et al. The OncoArray Consortium: a network for understanding the genetic architecture of common cancers. Cancer Epidemiol Biomarkers Prev 26 (2017), 126–135.
22. Feldman, R., Kim, E.S., Prognostic and predictive biomarkers post curative intent therapy. Ann Transl Med, 5, 2017, 374.
23. Martínez-Terroba, E., Behrens, C., de Miguel, F.J., et al. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early lung adenocarcinoma patients. J Pathol 245 (2018), 421–432.
24. Atkinson, A.J., Colburn, W.A., DeGruttola, V.G., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001), 89–95.
25. Mazzone, P.J., Sears, C.R., Arenberg, D.A., et al. Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An official American Thoracic Society policy statement. Am J Respir Crit Care Med 196 (2017), e15–e29.
26. Pepe, M.S., Etzioni, R., Feng, Z., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93 (2001), 1054–1061.
27. Atwater, T., Cook, C., Massion, P., The pursuit of noninvasive diagnosis of lung cancer. Semin Respir Crit Care Med 37 (2016), 670–680.
28. Rodriguez, H., Težak, Ž., Mesri, M., et al. Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin Chem 56 (2010), 237–243.
29. Pecot, C.V., Li, M., Zhang, X.J., et al. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev 21 (2012), 786–792.
30. Silvestri, G.A., Vachani, A., Whitney, D., et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med 373 (2015), 243–251.
31. Lam, S., Boyle, P., Healey, G.F., et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res 4 (2011), 1126–1134.
32. Macdonald, I.K., Murray, A., Healey, G.F., et al. Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT®-Lung test. PLoS One, 7, 2012, e51002.
33. Chapman, C.J., Healey, G.F., Murray, A., et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biol 33 (2012), 1319–1326.
34. Healey, G.F., Lam, S., Boyle, P., Hamilton-Fairley, G., Peek, L.J., Robertson, J.F.R., Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer. J Thorac Dis 5 (2013), 618–625.
35. Jett, J.R., Peek, L.J., Fredericks, L., Jewell, W., Pingleton, W.W., Robertson, J.F.R., Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer 83 (2014), 51–55.
36. Massion, P.P., Healey, G.F., Peek, L.J., et al. Autoantibody signature enhances the positive predictive power of computed tomography and nodule-based risk models for detection of lung cancer. J Thorac Oncol 12 (2017), 578–584.
37. Sullivan, F.M., Farmer, E., Mair, F.S., et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer, 17, 2017, 187.
38. Edelsberg, J., Weycker, D., Atwood, M., Hamilton-fairley, G., Jett, R., Cost-effectiveness of an autoantibody test (Early CDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules. Oncoimmunology 442 (2018), 1–14.
39. Boyle, P., Chapman, C.J., Holdenrieder, S., et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 22 (2011), 383–389.
40. Doseeva, V., Colpitts, T., Gao, G., Woodcock, J., Knezevic, V., Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med, 13, 2015, 55.
41. Ajona, D., Pajares, M.J., Corrales, L., et al. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst 105 (2013), 1385–1395.
42. Ajona, D., Okrój, M., Pajares, M.J., et al. Complement C4d-specific antibodies for the diagnosis of lung cancer. Oncotarget 9 (2018), 6346–6355.
43. Verri, C., Borzi, C., Holscher, T., et al. Mutational profile from targeted NGS predicts survival in LDCT screening–detected lung cancers. J Thorac Oncol 12 (2017), 922–931.
44. Sozzi, G., Boeri, M., Rossi, M., et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 32 (2014), 768–773.
45. Montani, F., Marzi, M.J., Dezi, F., et al. MiR-test: a blood test for lung cancer early detection. J Natl Cancer Inst, 107, 2015, djv063.
46. Sestini, S., Boeri, M., Marchiano, A., et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. Oncotarget 6 (2015), 32868–32877.
47. Jenkins, S., Yang, J.C.H., Ramalingam, S.S., et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer. J Thorac Oncol 12 (2017), 1061–1070.
48. Giroux Leprieur, E., Herbretau, G., Dumenil, C., et al. Circulating tumor DNA evaluated by next-generation sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. Oncoimmunology, 7, 2018, e1424675.
49. Merker, J.D., Oxnard, G.R., Compton, C., et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol 36 (2018), 1631–1641.
50. Abbosh, C., Birkbak, N.J., Wilson, G.A., et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545 (2017), 446–451.
51. Cohen, J.D., Li, L., Wang, Y., et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359 (2018), 926–930.
52. Ehrlich, M., DNA hypomethylation in cancer cells. Epigenomics 1 (2009), 239–259.
53. Esteller, M., Sanchez-Cespedes, M., Resell, R., Sidransky, D., Baylin, S.B., Herman, J.G., Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59 (1999), 67–70.
54. Wielscher, M., Vierlinger, K., Kegler, U., Ziesche, R., Gsur, A., Weinhäusel, A., Diagnostic performance of plasma DNA methylation profiles in lung cancer, pulmonary fibrosis and COPD. EBioMedicine 2 (2015), 929–936.
55. Ooki, A., Maleki, Z., Tsay, J.C.J., et al. A panel of novel detection and prognostic methylated DNA markers in primary non–small cell lung cancer and serum DNA. Clin Cancer Res 23 (2017), 7141–7152.
56. Hulbert, A., Jusue Torres, I., Stark, A., et al. Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum. Clin Cancer Res 23 (2016), 1998–2005.
57. Mazzone, P.J., Wang, X., Han, X., et al. Evaluation of a serum lung cancer biomarker panel. Biomark Insights, 13, 2018 1177271917751608.
58. Molina, R., Marrades, R.M., Augé, J.M., et al. Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med 193 (2016), 427–437.
59. Silvestri, G.A., Tanner, N.T., Kearney, P., et al. Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (PulmonAry NOdule Plasma proTeomIc Classifier) trial. Chest 154 (2018), 491–500.
60. Billatos, E., Vick, J.L., Lenburg, M.E., Spira, A.E., The airway transcriptome as a biomarker for early lung cancer detection. Clin Cancer Res 24 (2018), 2984–2992.
61. Spira, A., Beane, J.E., Shah, V., et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 13 (2007), 361–366.
62. Blomquist, T., Crawford, E.L., Mullins, D., et al. Pattern of antioxidant and DNA repair gene expression in normal airway epithelium associated with lung cancer diagnosis. Cancer Res 69 (2009), 8629–8635.
63. Whitney, D.H., Elashoff, M.R., Porta-Smith, K., et al. Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy. BMC Med Genomics, 8, 2015, 18.
64. Hu, Z., Whitney, D., Anderson, J.R., et al. Analytical performance of a bronchial genomic classifier. BMC Cancer, 16, 2016, 161.
65. Vachani, A., Whitney, D.H., Parsons, E.C., et al. Clinical utility of a bronchial genomic classifier in patients with suspected lung cancer. Chest 150 (2016), 210–218.
66. Hogarth DK, Dotson TL, Lee HL, Whitten PE, Smith K, Lenburg ME. The Percepta® Registry: a prospective registry to evaluate percepta bronchial genomic classifier patient data. Paper presented at: CHEST Annual Meeting. October 22–26, 2016; Los Angeles, CA.
67. AEGIS Study Team Perez-Rogers, J.F., Gerrein, J., et al. Shared gene expression alterations in nasal and bronchial epithelium for lung cancer detection. J Natl Cancer Inst, 109(7), 2017.
68. Boeri, M., Sestini, S., Fortunato, O., et al. Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging. Expert Rev Mol Diagn 15 (2015), 801–813.
69. Filippo, L., Principe, R., Cesario, A., et al. Smoking cessation intervention within the framework of a lung cancer screening program: preliminary results and clinical perspectives from the “Cosmos-II” Trial. Lung 193 (2015), 147–149.
70. Smyth, R.J., Toomey, S.M., Sartori, A., et al. Brief report on the detection of the EGFR-T790M mutation in exhaled breath condensate from lung cancer patients. J Thorac Oncol 13 (2018), 1213–1216.
71. Mazzone, P.J., Wang, X.F., Lim, S., et al. Progress in the development of volatile exhaled breath signatures of lung cancer. Ann Am Thorac Soc 12 (2015), 752–757.
72. Nakhleh, M.K., Amal, H., Jeries, R., et al. Diagnosis and classification of 17 diseases from 1404 subjects via pattern analysis of exhaled molecules. ACS Nano 11 (2017), 112–125.
73. Peled, N., Hakim, M., Bunn, P.A., et al. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol 7 (2012), 1528–1533.
74. Nardi-Agmon, I., Abud-Hawa, M., Liran, O., et al. Exhaled breath analysis for monitoring response to treatment in advanced lung cancer. J Thorac Oncol 11 (2016), 827–837.
75. Hakim, M., Broza, Y.Y., Barash, O., et al. Volatile organic compounds of lung cancer and possible biochemical pathways. Chem Rev 112 (2012), 5949–5966.
76. Peled, N., Barash, O., Tisch, U., et al. Volatile fingerprints of cancer specific genetic mutations. Nanomedicine 9 (2013), 758–766.
77. Peng, G., Hakim, M., Broza, Y.Y., et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer 103 (2010), 542–551.
78. Meyer, M.G., Hayenga, J.W., Neumann, T., et al. The Cell-CT 3-dimensional cell imaging technology platform enables the detection of lung cancer using the noninvasive LuCED sputum test. Cancer Cytopathol 123 (2015), 512–523.
79. Nelson, A., Meyer, M., Katdare, R., et al. Early detection of lung cancer based on three-dimensional, morphometric analysis of cells from sputum [abstract]. J Clin Oncol, 32, 2014, 7547.
80. Yu, L., Li, K., Zhang, X., Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review. Oncotarget 8 (2017), 115774–115786.
81. Puchades-Carrasco, L., Jantus-Lewintre, E., Pérez-Rambla, C., et al. Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer. Oncotarget 7 (2016), 12904–12916.
82. Rezola, A., Pey, J., Rubio, Á., Planes, F.J., In-silico prediction of key metabolic differences between two non-small cell lung cancer subtypes. PLoS One, 9, 2014, e103998.
83. Caiola, E., Brunelli, L., Marabese, M., Broggini, M., Lupi, M., Pastorelli, R., Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Oncotarget 7 (2016), 51462–51472.
84. Mathé, E.A., Patterson, A.D., Haznadar, M., et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res 74 (2014), 3259–3270.
85. Haznadar, M., Cai, Q., Krausz, K.W., et al. Urinary metabolite risk biomarkers of lung cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 25 (2016), 978–986.
86. Roś-Mazurczyk, M., Wojakowska, A., Marczak, Ł., et al. Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study. Acta Biochim Pol 64 (2017), 513–518.
87. Wikoff, W.R., Hanash, S., DeFelice, B., et al. Diacetylspermine is a novel prediagnostic serum biomarker for non-small-cell lung cancer and has additive performance with pro-surfactant protein B. J Clin Oncol 33 (2015), 3880–3886.
88. Wen, C.P., Zhang, F., Liang, D., et al. The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Clin Cancer Res 21 (2015), 193–200.
89. Fahrmann, J.F., Grapov, D., Defelice, B.C., et al. Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. Cancer Biomarkers 16 (2016), 609–617.
90. Cameron, S.J.S., Lewis, K.E., Beckmann, M., et al. The metabolomic detection of lung cancer biomarkers in sputum. Lung Cancer 94 (2016), 88–95.
91. Peralbo-Molina, A., Calderón-Santiago, M., Priego-Capote, F., Jurado-Gámez, B., Luque De Castro, M.D., Identification of metabolomics panels for potential lung cancer screening by analysis of exhaled breath condensate. J Breath Res, 10, 2016, 026002.
92. Lee, S.H., Sung, J.Y., Yong, D., et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer 102 (2016), 89–95.
93. Cassidy, A., Myles, J.P., Van Tongeren, M., et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 98 (2008), 270–276.
94. McKay, J.D., Hung, R.J., Han, Y., et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet 49 (2017), 1126–1132.
95. Field, J.K., Duffy, S.W., Baldwin, D.R., et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess (Rockv) 20 (2016), 1–146.
96. Ji, X., Bossé, Y., Landi, M.T., et al. Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun, 9, 2018, 3221.
97. Fusco JP, Pita G, Pajares MJ, et al. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer [e-pub ahead of print]. Cancer Med. https://doi.org/10.1002/cam4.1500, accessed.
98. Mieth, B., Kloft, M., Rodríguez, J.A., et al. Combining multiple hypothesis testing with machine learning increases the statistical power of genome-wide association studies. Sci Rep, 6, 2016, 36671.
99. Schrider, D.R., Kern, A.D., Supervised machine learning for population genetics: a new paradigm. Trends Genet 34 (2018), 301–312.
100. Lambin, P., Rios-Velazquez, E., Leijenaar, R., et al. Radiomics: Extracting more information from medical images using advanced feature analysis. Eur J Cancer 48 (2012), 441–446.
101. Chen, B., Zhang, R., Gan, Y., Yang, L., Li, W., Development and clinical application of radiomics in lung cancer. Radiat Oncol, 12, 2017, 154.
102. Shen, W., Zhou, M., Yang, F., Yang, C., Tian, J., Multi-scale convolutional neural networks for lung nodule classification. Inf Process Med Imaging 24 (2015), 588–599.
103. Arindra, A., Setio, A., Ciompi, F., et al. Pulmonary nodule detection in CT images: false positive reduction using multi-view convolutional networks. IEEE Trans Med Imaging 35 (2016), 1160–1169.
104. Liu, Y., Kim, J., Balagurunathan, Y., et al. Radiomic features are associated with egfr mutation status in lung adenocarcinomas. Clin Lung Cancer 17 (2016), 441–448.
105. Rios Velazquez, E., Parmar, C., Liu, Y., et al. Somatic mutations drive distinct imaging phenotypes in lung cancer. Cancer Res 77 (2017), 3922–3930.
106. Lee, J., Li, B., Cui, Y., et al. A quantitative CT imaging signature predicts survival and complements established prognosticators in stage I non-small cell lung cancer. Int J Radiat Oncol 102 (2018), 1098–1106.
107. Lin, Y., Leng, Q., Jiang, Z., et al. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules. Int J Cancer 141 (2017), 1240–1248.
108. Ma, J., Guarnera, M.A., Zhou, W., Fang, H., Jiang, F., A prediction model based on biomarkers and clinical characteristics for detection of lung cancer in pulmonary nodules. Transl Oncol 10 (2017), 40–45.
109. Jiang, R., Dong, X., Zhu, W., et al. Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers. PLoS One, 12, 2017, e0184338.
110. Jiang, F., Todd, N.W., Qiu, Q., Liu, Z., Katz, R.L., Stass, S.A., Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. Lung Cancer 66 (2009), 58–63.
111. Grossmann P, Stringfield O, El-Hachem N, et al. Defining the biological basis of radiomic phenotypes in lung cancer. Elife. https://doi.org/10.7554/eLife.23421. Accessed June 26, 2018.
112. GR. Oxnard T. Maddala E. Hubbell et al. Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): the Circulating Cancer Genome Atlas (CCGA) study. Paper presented at: 2018 American Society of Clinical Oncology Annual Meeting. June 1–5, 2018; Chicago, IL.
113. Aravanis, A.M., Lee, M., Klausner, R.D., Next-generation sequencing of circulating tumor dna for early cancer detection. Cell 168 (2017), 571–574.
114. Tuck, M.K., Chan, D.W., Chia, D., et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 8 (2009), 113–117.
115. Minari, J., Brothers, K.B., Morrison, M., Tensions in ethics and policy created by National Precision Medicine Programs. Hum Genomics, 12, 2018, 22.
116. Liu, L., Teng, J., Zhang, L., et al. The combination of the tumor markers suggests the histological diagnosis of lung cancer. Biomed Res Int, 2017, 2017, 2013989.
117. Boeri, M., Verri, C., Conte, D., et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci 108 (2011), 3713–3718.
118. Bianchi, F., Nicassio, F., Marzi, M., et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 3 (2011), 495–503.
119. Maisonneuve, P., Bagnardi, V., Bellomi, M., et al. Lung cancer risk prediction to select smokers for screening CT–a model based on the Italian COSMOS trial. Cancer Prev Res (Phila) 4 (2011), 1778–1789.
120. Yanaihara, N., Caplen, N., Bowman, E., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9 (2006), 189–198.
121. Weiss, G., Schlegel, A., Kottwitz, D., König, T., Tetzner, R., Validation of the SHOX2/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. J Thorac Oncol 12 (2017), 77–84.
122. Newman, A.M., Bratman, S.V., To, J., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20 (2014), 548–554.
123. Guo, N., Lou, F., Ma, Y., et al. Circulating tumor DNA detection in lung cancer patients before and after surgery. Sci Rep, 6, 2016, 33519.
124. Phallen, J., Sausen, M., Adleff, V., et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med, 9, 2017.
125. Showe, M.K., Vachani, A., Kossenkov, A.V., et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 69 (2009), 9202–9210.
126. Halling, K.C., Rickman, O.B., Kipp, B.R., Harwood, A.R., Doerr, C.H., Jett, J.R., A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest 130 (2006), 694–701.
127. Nichols, J.A.A., Grob, P., de Lusignan, S., Kite, W., Williams, P., Genetic test to stop smoking (GeTSS) trial protocol: randomised controlled trial of a genetic test (Respiragene) and Auckland formula to assess lung cancer risk. BMC Pulm Med, 14, 2014, 77.
128. Zhang, C., Yu, W., Wang, L., et al. DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis. J Cancer 8 (2017), 3585–3591.
129. Xing, L., Su, J., Guarnera, M.A., et al. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. Clin Cancer Res 21 (2015), 484–489.
130. Subramanian, H., Viswanathan, P., Cherkezyan, L., et al. Procedures for risk-stratification of lung cancer using buccal nanocytology. Biomed Opt Express 7:9 (2016), 3795–3810.
131. Patriquin, L., Merrick, D.T., Hill, D., et al. Early detection of lung cancer with meso tetra (4-carboxyphenyl) porphyrin-labeled sputum. J Thorac Oncol 10 (2015), 1311–1318.